U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H31NO5S
Molecular Weight 421.55
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LATRUNCULIN A

SMILES

C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]3CSC(=O)N3)OC(=O)C=C(C)CC\C=C\C=C1

InChI

InChIKey=DDVBPZROPPMBLW-IZGXTMSKSA-N
InChI=1S/C22H31NO5S/c1-15-7-5-3-4-6-8-16(2)11-20(24)27-18-12-17(10-9-15)28-22(26,13-18)19-14-29-21(25)23-19/h3-5,7,11,15,17-19,26H,6,8-10,12-14H2,1-2H3,(H,23,25)/b4-3+,7-5-,16-11-/t15-,17-,18-,19+,22-/m1/s1

HIDE SMILES / InChI

Description

Latrunculin A is a naturally occurring toxin that can be purified from the red sea sponge Latrunculia magnifica. It disrupts actin polymerization and prevents mitotic spindle formation; therefore preventing proper cellular replication. It was discovered that latrunculin A has strong anticancer effects, and it was investigated as a treatment candidate for peritoneal dissemination of gastric cancer.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.2 µM [Kd]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
in mice: Mice bearing peritoneally disseminated MKN45 or NUGC-4 (gastric cancer cells) tumors were prepared by an i.p. inoculation of 1×107 cells in 5% DMSO/0.7 mL PBS. On day 3, 10 and 17 after tumor inoculation, each mouse was given an i.p.injection of latrunculin A. The i.p. injection group were treated with latrunculin A (0.05 mg/kg, 5% DMSO in 0.7 mL PBS, n=14, MKN45; and n=10, NUGC-4), and the control group was treated with 5% DMSO in 0.7 mL PBS (n=19, MKN45; and n=9, NUGC-4). Negative (n=10) group was given latrunculin A without tumor inoculation.
Route of Administration: Intraperitoneal
In Vitro Use Guide
It was reported that 25 µM Latrunculin A (LatA) blocked actin polymerization in the capacitated sperm head, resulting in a marked decrease in sperm with relocated IZUMO1 during the A23187-induced acrosome reaction and cumulus layer penetration. Treated sperm also exhibited reduced zona pellucida penetration and fertilizing capacity. Interestingly, LatA-treated sperm present in the perivitelline space of eggs did not show impaired IZUMO1 relocation.